Resources

Chris Molloy on Parliament Day, the EU start-up fund, MHRA rare disease regulation, Northern Ireland, women in biotech and scientific leadership

Overcoming regulatory hurdles to secure the UK’s place in the global engineering biology race

Fundraising, collaboration, IP and leadership in focus as founders and investors shared practical advice for scaling in the UK

Chris Molloy discusses Government engagement, the King’s Speech, health data, Isomorphic’s huge raise, the Start-up Festival and expanding BIA’s reach

Each month, our Policy and Public Affairs team will showcase how we are championing members’ voices in Government and Parliament

Four of the most significant opportunities currently available to engage with global industry leaders

BIA CEO Chris Molloy discusses the vision for data report, rare disease R&D, Women in Biotech, Europe GMO rules, Bio€quity and Swiss Biotech Day

In this guest blog, Catherine Hsu Steve Cardosi discuss Convertible Loan Notes (CLNs).

In this guest blog, Asma Aslam says that rising domestic costs and strong overseas capabilities are pushing companies to subcontract abroad.

It has been an extremely challenging time for biotech post COVID-19 boom, but our Q1 financing report offers hope with continued positive momentum.

In this blog, Ethan Almond reflects on the inaugral BioSolutions UK conference, which brought together over 200 innovators, policymakers and industry leaders alongside an additional 29 investors.

The UK BioIndustry Association (BIA) is the UK’s trade association for innovative life sciences and the leading UK-wide forum for expert communities and high quality peer-to-peer networking in the sector.

In this blog, Ethan Almond reflects on the successes and innovative technology of biosolutions company and BIA member twig.

In this guest blog, Lee Smith and Spiros Servos argue that early-stage biotech leaders who secure investment in 2026 are those who integrate commercial thinking early, aligning science, clinical strategy and market realities into a credible narrative for investors.

In this guest blog, Dan Stanton, Trade Media Expert at Sartorius Bioprocess Solutions, discusses how tight funding, manual tech transfer and product specific analytics are keeping cell and gene therapies (CGTs) from realising their potential.

Back from our Easter break, we’re hitting the ground running with an update on the publication of agreed text underpinning the UK-US pharmaceuticals agreement.

Each month, our Policy and Public Affairs team will showcase how we are championing members’ voices in Government and Parliament.

Lewis Miles discusses changes to EMIs, EISs and VCTs coming into force.

In this guest blog, Paul Jeffrey, Director of the GFIL/Cranfield Technology Accelerator at Cranfield Water Science Institute, explains how engineering biology solutions for environmental applications face unclear and complex regulatory pathways.

In this guest blog, Rubin Joshi, Business Development Manager at Aldevron, explains how scaling adeno-associated virus (AAV) manufacturing remains a major bottleneck for gene therapy development.